文献速递肾癌与肾肿瘤

血浆糖胺聚糖作为手术治疗肾细胞癌的诊断和预后生物标志物

Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2018-06-13

这项回顾性病例对照研究纳入175例手术治疗的肾细胞癌患者和19例健康对照,用毛细管电泳激光诱导荧光检测血浆糖胺聚糖(GAG)。新GAG评分在验证集中区分肾细胞癌与健康样本的AUC为0.991、敏感性93.5%,总硫酸软骨素浓度是全因生存和无复发生存的独立预后因素。

要点

  • 新GAG评分在验证集区分肾细胞癌与健康样本的AUC为0.991,敏感性93.5%。
  • GAG评分在肾细胞癌中升高,与分期、分级、组织学、年龄、性别无关。
  • 总硫酸软骨素浓度是全因生存和无复发生存的独立预后因素。

核心结论

  • 血浆GAG是手术治疗的肾细胞癌的高敏感性诊断和预后生物标志物,独立于分期、分级或组织学。
  • 作者认为需要对GAG评分用于肾细胞癌早期检测、预测和复发监测进行前瞻性验证研究。

研究设计与样本

  • 回顾性病例对照研究,纳入2011年5月至2014年2月连续手术治疗的175例肾细胞癌患者和19例健康对照。
  • 在单一盲法实验室用毛细管电泳激光诱导荧光测量术前和术后肾细胞癌及健康样本的血浆GAG。
  • 先分析发现集以更新历史GAG评分,再用剩余样本验证新GAG评分检测肾细胞癌 versus 健康受试者的敏感性。
  • 用非参数检验、对数秩检验和多变量Cox回归分析评估新GAG评分与组织病理学变量、全因生存和无复发生存的相关性。
  • 试验注册号为ClinicalTrial.gov NCT03471897。

主要发现

  • 肾细胞癌队列包括94例I期、58例II-III期和22例IV期病例。
  • 在发现集(n=67)中,新GAG评分区分肾细胞癌与健康样本的受试者工作特征曲线下面积(AUC)为0.999。
  • 在验证集(n=108)中,GAG评分的AUC为0.991,敏感性为93.5%。
  • GAG评分在肾细胞癌中较健康样本升高,与分期、分级、组织学、年龄或性别无关且不相关。
  • 总硫酸软骨素浓度是全因生存和无复发生存的独立预后因素(风险比分别为1.51和1.25),与病理诊断时可获得的变量联合时一致性指数(C-index)分别为0.926和0.849,与术前可获得的变量联合时C-index分别为0.846和0.736。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究的局限性包括其回顾性性质。
  • GAG实验室测量存在中等程度的变异性。
  • 作者认为需要对GAG评分用于肾细胞癌早期检测、预测和复发监测进行前瞻性验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma glycosaminoglycan (GAG) measurements, when aggregated into diagnostic scores, accurately distinguish metastatic clear-cell renal cell carcinoma (RCC) from healthy samples and correlate with prognosis. However, it is unknown if GAG scores can detect RCC in earlier stages or if they correlate with prognosis after surgery. OBJECTIVE: To explore the sensitivity and specificity of plasma GAGs for detection of early-stage RCC and prediction of recurrence and death after RCC surgery. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective case-control study consisting of a consecutive series of 175 RCC patients surgically treated between May 2011 and February 2014 and 19 healthy controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Plasma GAGs in preoperative and postoperative RCC and healthy samples were measured using capillary electrophoresis with laser-induced fluorescence in a single blinded laboratory. A discovery set was first analyzed to update the historical GAG score. The sensitivity of the new GAG score for RCC detection versus healthy subjects was validated using the remaining samples. The correlation of the new GAG score to histopathologic variables, overall survival, and recurrence-free survival was evaluated using nonparametric and log-rank tests and multivariable Cox regression analyses. RESULTS AND LIMITATIONS: The RCC cohort included 94 stage I, 58 stage II-III, and 22 stage IV cases. In the first discovery set (n=67), the new GAG score distinguished RCC from healthy samples with an area under the receiver operating characteristic curve (AUC) of 0.999. In the validation set (n=108), the GAG score achieved an AUC of 0.991, with 93.5% sensitivity. GAG scores were elevated in RCC compared to healthy samples, irrespective of and uncorrelated to stage, grade, histology, age, or gender. The total chondroitin sulfate concentration was an independent prognostic factor for both overall and recurrence-free survival (hazard ratios 1.51 and 1.25) with high concordance when combined with variables available at pathologic diagnosis (C-index 0.926 and 0.849) or preoperatively (C-index 0.846 and 0.736). Limitations of the study include its retrospective nature and moderate variability in GAG laboratory measurements. CONCLUSIONS: Plasma GAGs are highly sensitive diagnostic and prognostic biomarkers in surgically treated RCC independent of stage, grade, or histology. Prospective validation studies on GAG scores for early detection, prediction, and surveillance for RCC recurrence are thus warranted. PATIENT SUMMARY: In this study, we examined if a new molecular blood test can detect renal cell carcinoma in the early stages and predict if the cancer might relapse after surgery. The trial is registered on ClinicalTrial.gov as NCT03471897.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gatto F, Blum KA, Hosseini SS, et al. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. Eur Urol Oncol. 2018. PMID: 31158075. doi:10.1016/j.euo.2018.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。